Fri, Feb 27, 2015, 3:18 AM EST - U.S. Markets open in 6 hrs 12 mins


% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

  • brewman228 brewman228 Apr 17, 2013 7:56 PM Flag

    Getting more research coverage

    DUBLIN--(BUSINESS WIRE)--April 17, 2013--

    Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering.

    'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease.

    Reasons to buy

    - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease.
    - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
    - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
    - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.1699+0.0599(+5.40%)Feb 26 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.